Paper #906

Título:

The impact of generic reference pricing interventions in the statin market

Autor:

Jaume Puig

Data:

Diciembre 2005

Resumen:

The objective of this study was to evaluate the intended and unintended impact on pharmaceutical use and sales of three public financing reforms applied to the prescription of statins: a Spanish generic reference pricing (RP) system for lovastatin and simvastatin, and two competing policies introduced by the Andalusian Public Health Service (APHS) for all statins, first a maximum consumer price (MCP) and then a so called quality prescribing incentive for general practitioners (MCP plus PI). This study is designed as an observational, retrospective, interrupted time series analysis with comparison series (APHS and the rest of Spain) of 46 monthly drug use and sales ratios from January 2001 to October 2004 for each active ingredient in the group of statins. RP has been effective at reducing the volume of sales growth of the off-patent statins, yet its overall impact on sales of all statins has been relatively modest. The quantity and volume of sales impact heavily depends on regulatory RP details such as when the system is introduced, how often it is updated, and how the reference price is calculated.

Palabras clave:

Pharmaceutical sales, generic medicines, pharmaceutical reference pricing, statins

Códigos JEL:

I18, H5

Área de investigación:

Economía Laboral, Pública, de Desarrollo y de la Salud

Númuero serie CRES:

45

Descargar el paper en formato PDF